Loading
companiesCompany
Immuneel Therapeutics
A Bengaluru cell therapy company that brought Barcelona's academic CD19 CAR-T to India as Qartemi, the country's second approved CAR-T, after the IMAGINE trial.
Overview
Immuneel Therapeutics is a private cell and gene therapy company based at Narayana Health City in Bengaluru, formed to make CAR-T therapy affordable and accessible in India. Its lead product, varnimcabtagene autoleucel (IMN-003A, brand Qartemi), is the Indian version of ARI-0001, the academic CD19 CAR-T developed at Hospital Clinic de Barcelona and approved in Spain under the hospital exemption. Immuneel ran IMAGINE, the first industry-sponsored CAR-T trial in India, a phase 2 study in relapsed or refractory B-cell malignancies reported at ASH 2023 and in Hematological Oncology, and Qartemi received CDSCO market authorisation for relapsed or refractory B-cell lymphoma in 2024. The company won Endpoints' most promising biopharma start-up and APAC cell and gene therapy start-up awards in 2023.
Headquarters
Bengaluru, IN
Scorecard
All companies#337of 1244 companies, score 11
- approved products +6
- targets +2
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Website
ApprovedCAR-T (CD19, academic origin)
Varnimcabtagene autoleucel · Qartemi
India's second approved CAR-T therapy, a Bengaluru-made version of a Spanish hospital's academic CD19 cell therapy, for lymphoma that has come back after other treatments.
Similar pages
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, CAR-T cell therapy.
- PersonRahul Purwar
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
- IdeaNon-profit, open-licence lentiviral vectors and producer cell lines for CAR-T
Shares Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care, CAR-T cell therapy.
- TreatmentTalicabtagene autoleucel
Shares Varnimcabtagene autoleucel, Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines.
- InstitutionIndian Institute of Technology Bombay
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CD19, Most of the world has almost no cancer care.
- TrialTalicabtagene autoleucel (NexCAR19) phase 1/2
Shares Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyImmunoACT
Shares Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, CD19.
cancers
fronts
technologies
targets
drugs
ApprovedCAR-T (CD19, academic origin)
Varnimcabtagene autoleucel · Qartemi